No Stock Yet
Dongfulong (300171): Revenue continues to grow steadily
Dongfulong (300171): Revenue increased 29.6% year-on-year in the third quarter alone and continued to promote internationalization & diversification
Dongfulong (300171): The pace of Q3 order delivery is improving, starting a new round of capacity expansion
Dongfulong (300171): Revenue side growth is in line with expectations, short-term gross margin falls, putting pressure on profit side
Dongfulong (300171): Pharmaceutical equipment leader creates second growth curve for consumables, CGT, etc.
Dongfulong (300171) In-depth Report: Jiaolong's Whole Industry Integration Strategy Breaks the Cycle When Going Overseas
Dongfulong (300171): The epidemic disrupts growth, slows down production capacity optimization, unleashes potential
Dongfulong (300171): Expectations that overseas business will continue to develop throughout the year without changing the impact of the epidemic
East Fulong (300171): the company's overall performance is under pressure due to the impact of the steady epidemic situation in the second quarter.
East Fulong (300171): the performance is in line with the expected overseas growth in the context of the epidemic, which is expected to open up room for long-term growth.
No Stock Yet